RBC Capital Markets is betting that Eli Lilly's blockbuster obesity treatments will power a strong second-quarter earnings beat when the pharmaceutical giant reports on August 5th. The investment bank expects the company to potentially raise its full-year outlook again, driven by surging sales of Zepbound and Mounjaro.
What RBC Is Forecasting
In a preview note, RBC analysts projected quarterly revenue of $20.74 billion, above the $20.51 billion consensus estimate from Visible Alpha. The bank specifically sees sales of Zepbound (approved for weight loss) and Mounjaro (approved for diabetes) beating forecasts by 5% to 6%. Strong demand in both the U.S. and international markets is expected to offset what RBC describes as "low-to-mid-teens" pricing pressure.
However, not all of Lilly's portfolio is firing on all cylinders. RBC notes that other drugs like the breast cancer treatment Verzenio and the diabetes medication Trulicity are expected to weigh on overall results. This mixed picture highlights the company's heavy reliance on its GLP-1 franchise, which has become the centerpiece of its growth story.
The Broader Context
Eli Lilly has been at the forefront of the obesity drug revolution, competing with Novo Nordisk's Wegovy and Ozempic. The GLP-1 receptor agonist class has exploded in popularity, with analysts estimating the market could be worth over $100 billion annually by the end of the decade. Lilly's Zepbound received FDA approval for chronic weight management in late 2023, and Mounjaro has been a top seller for diabetes since its 2022 launch.
The company has already raised its 2024 guidance twice this year, reflecting confidence in production capacity and demand. A third raise would signal that supply constraints are easing and that the company is capturing more market share than anticipated. This comes against a backdrop of broader economic uncertainty, with US consumer inflation expectations ticking up and Treasury yields falling after a weak jobs report, factors that can influence healthcare spending and investor sentiment.
What It Means for Investors
For everyday investors, this preview underscores the importance of understanding which products drive a company's earnings. Eli Lilly's stock has more than doubled over the past two years, largely on the promise of its obesity drugs. A beat and guidance raise could provide further momentum, but it also raises the bar for future quarters.
Investors should watch for several key details in the August 5th report: actual Zepbound and Mounjaro sales figures, commentary on manufacturing capacity, and any updates on pipeline drugs. The company is also developing next-generation obesity treatments, including oral versions that could expand the market further.
Pricing pressure is a notable risk. While demand is strong, insurers and pharmacy benefit managers are pushing back on high list prices. RBC's mention of "low-to-mid-teens" pricing pressure suggests that net revenue per prescription may be declining even as volume grows. This dynamic is common in the pharmaceutical industry, where rebates and discounts can significantly reduce top-line growth.
The broader market context also matters. With the dollar slipping after a cool jobs report, international sales become more valuable for U.S.-based companies like Lilly. A weaker dollar boosts the value of overseas revenue when converted back to dollars, which could provide an additional tailwind.
Looking Ahead
Eli Lilly's earnings will be closely watched not just for the numbers, but for what they signal about the trajectory of the obesity drug market. If RBC is correct, the company is on track for another strong quarter, reinforcing its position as a leader in one of the fastest-growing areas of medicine.
However, investors should remember that high expectations can be a double-edged sword. Stocks that beat estimates can still fall if the market was hoping for even more. The key is to focus on the underlying trends: are prescriptions accelerating? Is the company gaining market share? Are manufacturing constraints easing? These fundamentals will matter more than any single quarter's beat.
For now, RBC's confidence provides a positive signal, but the actual results on August 5th will tell the real story.
